Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update on key programs
Promising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Patient enrollment continues in the Phase 1b/2 KEYNOTE B84 oncology and Phase 1/2a SIGNAL-AD Alzheimer’s studies
Several posters and presentations expected at November Medical Meetings, the Society for Immunotherapy of Cancer (SITC 2022) and Huntington’s Study Group (HSG 2022)
ROCHESTER, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update on key programs.
